{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:13:59Z","timestamp":1793164439524,"version":"4.5.0"},"reference-count":53,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1202804, 2023YFC2510000,2024YFA1210201"],"award-info":[{"award-number":["2022YFF1202804, 2023YFC2510000,2024YFA1210201"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373018\uff0c82473295"],"award-info":[{"award-number":["82373018\uff0c82473295"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academician Expert Workstation Grants","award":["S182023110190129357"],"award-info":[{"award-number":["S182023110190129357"]}]},{"name":"Medical Innovation Research Project of Shanghai Science and Technology Commission","award":["23Y11906200"],"award-info":[{"award-number":["23Y11906200"]}]},{"name":"Fudan University Medical Engineering Integration Project","award":["IDH2310155"],"award-info":[{"award-number":["IDH2310155"]}]},{"name":"Dawn Program of Shanghai Education Commission","award":["23SG07"],"award-info":[{"award-number":["23SG07"]}]},{"name":"Medical Innovation Research Project of Shanghai Science and Technology Commission","award":["20234Z0009"],"award-info":[{"award-number":["20234Z0009"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis and limited treatment options. Oncolytic virus (OV) therapy holds promise but is hindered by immune neutralization and poor tumor infiltration. Neural stem cells (NSCs) can enhance OV delivery, and intracerebroventricular (ICV) administration offers broader tumor access. This study evaluates NSC-OV therapy via ICV injection for improved tumor targeting and immune modulation in GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NSCs were infected with OV and assessed for viral uptake and replication. In vitro assays examined NSC-OV effects on glioma proliferation and migration. In vivo xenograft and orthotopic models evaluated tumor targeting, therapeutic efficacy, and immune modulation. Humanized immune system mouse models enabled single-cell RNA sequencing and flow cytometry analysis of immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NSCs retained their stemness after OV infection. NSCs-OV significantly inhibited glioma cell migration, proliferation, and colony formation in vitro. In orthotopic GBM models, NSCs-OV exhibited enhanced tumor homing, prolonged viral persistence, and reduced tumor burden while minimizing inflammation and systemic toxicity. NSCs protected OV from neutralizing antibodies, leading to sustained efficacy. Single-cell RNA sequencing indicated that NSCs-OV therapy reduced tumor-promoting inflammation by downregulating S100A8\/A9, markers of myeloid-derived suppressor cells (MDSCs) and chemotactic factors that recruited MDSCs into tumors. Combining NSCs-OV with Paquinimod further suppressed tumor growth by reducing MDSCs and increasing activated T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NSCs serve as efficient OV carriers, enhancing tumor targeting, suppressing GBM progression, and modulating the immune landscape. The combination with Paquinimod amplifies therapeutic benefits, offering a promising strategy for improving GBM treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012934","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:35:24Z","timestamp":1759916124000},"page":"e012934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Neural stem cell-delivered oncolytic virus via intracerebroventricular administration enhances glioblastoma therapy and immune modulation"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05180851","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-8586","authenticated-orcid":false,"given":"Huihui","family":"Chai","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruize","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical, Shanghai Anji Xiekang Biotechnology Company Limited, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical, Shanghai Anji Xiekang Biotechnology Company Limited, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company, Shang Hai, China"},{"name":"Institute of Smart Biomedical Materials, Zhejiang Sci-Tech University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Feng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Huashan Hospital, Shang Hai, China"},{"name":"National Center for Neurological Disorders, Shang Hai, China"},{"name":"Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shang Hai, China"},{"name":"Neurosurgical Institute of Fudan University, Shang Hai, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shang Hai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"2025111301351858000_13.10.e012934.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780"},{"key":"2025111301351858000_13.10.e012934.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05301-9"},{"key":"2025111301351858000_13.10.e012934.3","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1038\/s41598-025-88458-7","article-title":"Semantic structure preservation for accurate multi-modal glioma diagnosis","volume":"15","author":"Shi","year":"2025","journal-title":"Sci Rep"},{"key":"2025111301351858000_13.10.e012934.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025111301351858000_13.10.e012934.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01848","article-title":"Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study","volume":"10","author":"Marchini","year":"2019","journal-title":"Front Immunol"},{"key":"2025111301351858000_13.10.e012934.6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.20892\/j.issn.2095-3941.2024.0390","article-title":"Improving systemic delivery of oncolytic virus by cellular carriers","volume":"21","author":"Peng","year":"2025","journal-title":"Cancer Biol Med"},{"key":"2025111301351858000_13.10.e012934.7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1450203","article-title":"Strategies for engineering oncolytic viruses to enhance cancer immunotherapy","volume":"15","author":"Yin","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025111301351858000_13.10.e012934.8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"2025111301351858000_13.10.e012934.9","doi-asserted-by":"crossref","DOI":"10.3390\/v15020547","article-title":"Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies","volume":"15","author":"Hamad","year":"2023","journal-title":"Viruses"},{"key":"2025111301351858000_13.10.e012934.10","doi-asserted-by":"crossref","DOI":"10.1038\/s44276-024-00051-z","article-title":"Viruses in glioblastoma: an update on evidence and clinical trials","volume":"2","author":"Gunasegaran","year":"2024","journal-title":"BJC Rep"},{"key":"2025111301351858000_13.10.e012934.11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00061","article-title":"DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report","volume":"8","author":"Tejada","year":"2018","journal-title":"Front Oncol"},{"key":"2025111301351858000_13.10.e012934.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun"},{"key":"2025111301351858000_13.10.e012934.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x"},{"key":"2025111301351858000_13.10.e012934.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004462","article-title":"The use of oncolytic virotherapy in the neoadjuvant setting","volume":"10","author":"Thomas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025111301351858000_13.10.e012934.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44576-2","article-title":"Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"2025111301351858000_13.10.e012934.16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17625"},{"key":"2025111301351858000_13.10.e012934.17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/neuonc\/noad172","article-title":"NLGN4X TCR transgenic T cells to treat gliomas","volume":"26","author":"Kr\u00e4mer","year":"2024","journal-title":"Neuro Oncol"},{"key":"2025111301351858000_13.10.e012934.18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jcyt.2017.02.002","article-title":"Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas","volume":"19","author":"Parker Kerrigan","year":"2017","journal-title":"Cytotherapy"},{"key":"2025111301351858000_13.10.e012934.19","article-title":"Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies","volume":"12","author":"Shah","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"2025111301351858000_13.10.e012934.20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00245-x"},{"key":"2025111301351858000_13.10.e012934.21","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.100"},{"key":"2025111301351858000_13.10.e012934.22","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2013-0039"},{"key":"2025111301351858000_13.10.e012934.23","doi-asserted-by":"publisher","DOI":"10.1021\/mp200161f"},{"key":"2025111301351858000_13.10.e012934.24","doi-asserted-by":"crossref","unstructured":"Chua CYX , Ho J , Demaria S , et al . Emerging Technologies for Local Cancer Treatment. Advanced Therapeutics 2020;3. doi:10.1002\/adtp.202000027","DOI":"10.1002\/adtp.202000027"},{"key":"2025111301351858000_13.10.e012934.25","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090895","article-title":"Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials","volume":"12","author":"Brady","year":"2020","journal-title":"Pharmaceutics"},{"key":"2025111301351858000_13.10.e012934.26","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/neuonc\/nou360","article-title":"Polymeric drug delivery for the treatment of glioblastoma","volume":"17 Suppl 2","author":"Wait","year":"2015","journal-title":"Neuro Oncol"},{"key":"2025111301351858000_13.10.e012934.27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008999","article-title":"Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial","volume":"12","author":"He","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025111301351858000_13.10.e012934.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1382"},{"key":"2025111301351858000_13.10.e012934.29","article-title":"Creation of \u201chumanized\u201d mice to study human immunity","volume":"Chapter 15","author":"Pearson","year":"2008","journal-title":"Curr Protoc Immunol"},{"key":"2025111301351858000_13.10.e012934.30","doi-asserted-by":"crossref","DOI":"10.1002\/cpsc.113","article-title":"Humanized Mouse Models for Evaluation of PSC Immunogenicity","volume":"54","author":"Hermsen","year":"2020","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"2025111301351858000_13.10.e012934.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00721-2"},{"key":"2025111301351858000_13.10.e012934.32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41419-024-06849-6","article-title":"S100A8\/A9hi neutrophils induce mitochondrial dysfunction and PANoptosis in endothelial cells via mitochondrial complex I deficiency during sepsis","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"2025111301351858000_13.10.e012934.33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.omto.2017.05.001","article-title":"A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model","volume":"5","author":"Kim","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"2025111301351858000_13.10.e012934.34","doi-asserted-by":"crossref","unstructured":"Brunetti-Pierri N , SpringerLink . Safety and efficacy of gene-based therapeutics for inherited disorders. 1st edn. Cham: Springer International Publishing, 2017.","DOI":"10.1007\/978-3-319-53457-2_1"},{"key":"2025111301351858000_13.10.e012934.35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s15010-024-02455-y","article-title":"Adenovirus nephritis in adult kidney allograft recipients: a systematic review of literature","volume":"53","author":"Kiran","year":"2025","journal-title":"Infection"},{"key":"2025111301351858000_13.10.e012934.36","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"2025111301351858000_13.10.e012934.37","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.740827","article-title":"Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression","volume":"9","author":"Cheng","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025111301351858000_13.10.e012934.38","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-023-04652-x","article-title":"Therapeutic S100A8\/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction","volume":"27","author":"Jakobsson","year":"2023","journal-title":"Crit Care"},{"key":"2025111301351858000_13.10.e012934.39","doi-asserted-by":"crossref","first-page":"119619","DOI":"10.1016\/j.bbamcr.2023.119619","article-title":"Glioma-derived S100A9 polarizes M2 microglia to inhibit CD8+T lymphocytes for immunosuppression via \u03b1v\u03b23 integrin\/AKT1\/TGF\u03b21","volume":"1871","author":"Huang","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2025111301351858000_13.10.e012934.40","first-page":"11513","article-title":"S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages","volume":"16","author":"Ji","year":"2024","journal-title":"Aging (Milano)"},{"key":"2025111301351858000_13.10.e012934.41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41417-024-00740-4","article-title":"Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"2025111301351858000_13.10.e012934.42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1187741"},{"key":"2025111301351858000_13.10.e012934.43","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16070953","article-title":"Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells","volume":"16","author":"Cornelissen","year":"2024","journal-title":"Pharmaceutics"},{"key":"2025111301351858000_13.10.e012934.44","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1329712","article-title":"Therapeutic role of neural stem cells in neurological diseases","volume":"12","author":"Yang","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"2025111301351858000_13.10.e012934.45","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1206111","article-title":"Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells","volume":"13","author":"Kardani","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025111301351858000_13.10.e012934.46","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0224"},{"key":"2025111301351858000_13.10.e012934.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00208.x"},{"key":"2025111301351858000_13.10.e012934.48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2022.228","article-title":"Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy","volume":"34","author":"Sheldon","year":"2023","journal-title":"Hum Gene Ther"},{"key":"2025111301351858000_13.10.e012934.49","doi-asserted-by":"crossref","first-page":"112922","DOI":"10.1016\/j.intimp.2024.112922","article-title":"Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma","volume":"141","author":"Yin","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2025111301351858000_13.10.e012934.50","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"2025111301351858000_13.10.e012934.51","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01995-y","article-title":"MDSC: a new potential breakthrough in CAR-T therapy for solid tumors","volume":"22","author":"Abdalsalam","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2025111301351858000_13.10.e012934.52","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1093\/annonc\/mdx487","article-title":"A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy","volume":"28","author":"Fizazi","year":"2017","journal-title":"Ann Oncol"},{"key":"2025111301351858000_13.10.e012934.53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1479502","article-title":"Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity","volume":"15","author":"Demir","year":"2024","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:35:42Z","timestamp":1763026542000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jitc-2025-012934"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012934","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}